Product: PSPH Antibody
Catalog: DF12711
Description: Rabbit polyclonal antibody to PSPH
Application: WB IF/ICC
Cited expt.: WB
Reactivity: Human, Mouse, Rat
Prediction: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.: 25 kDa; 25kD(Calculated).
Uniprot: P78330
RRID: AB_2845672

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Zebrafish(83%), Bovine(100%), Horse(92%), Sheep(100%), Rabbit(92%), Dog(92%), Chicken(100%), Xenopus(92%)
Clonality:
Polyclonal
Specificity:
PSPH Antibody detects endogenous levels of total PSPH.
RRID:
AB_2845672
Cite Format: Affinity Biosciences Cat# DF12711, RRID:AB_2845672.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

EC 3.1.3.3; L 3 phosphoserine phosphatase; L-3-phosphoserine phosphatase; O phosphoserine phosphohydrolase; O-phosphoserine phosphohydrolase; Phosphoserine phosphatase; Phosphoserine phosphatase deficiency, included; PSP; PSPase; Psph; PSPHD; SERB_HUMAN;

Immunogens

Immunogen:

A synthesized peptide derived from human PSPH, corresponding to a region within the internal amino acids.

Uniprot:
Gene(ID):
Sequence:
MVSHSELRKLFYSADAVCFDVDSTVIREEGIDELAKICGVEDAVSEMTRRAMGGAVPFKAALTERLALIQPSREQVQRLIAEQPPHLTPGIRELVSRLQERNVQVFLISGGFRSIVEHVASKLNIPATNVFANRLKFYFNGEYAGFDETQPTAESGGKGKVIKLLKEKFHFKKIIMIGDGATDMEACPPADAFIGFGGNVIRQQVKDNAKWYITDFVELLGELEE

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Bovine
100
Sheep
100
Chicken
100
Horse
92
Dog
92
Xenopus
92
Rabbit
92
Zebrafish
83
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Catalyzes the last step in the biosynthesis of serine from carbohydrates. The reaction mechanism proceeds via the formation of a phosphoryl-enzyme intermediates.

Family&Domains:

Belongs to the HAD-like hydrolase superfamily. SerB family.

Research Fields

· Metabolism > Amino acid metabolism > Glycine, serine and threonine metabolism.

· Metabolism > Global and overview maps > Metabolic pathways.

· Metabolism > Global and overview maps > Carbon metabolism.

· Metabolism > Global and overview maps > Biosynthesis of amino acids.

References

1). Chemotherapy-induced macrophage CXCL7 expression drives tumor chemoresistance via the STAT1/PHGDH-serine metabolism axis and SAM paracrine feedback to M2 polarization. Cell death & disease, 2025 (PubMed: 40368902) [IF=8.1]

Application: WB    Species: human    Sample:

Fig. 4: CXCL7 upregulates PHGDH and activates serine metabolism in cancer cells. A Left: GSEA of enriched pathways in differentially expressed genes (DEGs) between HT29-control and HT29-CXCL7 groups. Right: Comparative analysis of PHGDH FPKM values between groups. B The expression level of PHGDH in control and CXCL7-overexpressing cells with or without the CXCR2 inhibitor, as determined by RT-qPCR. C Western blot detection of serine biosynthesis enzymes (PHGDH, PSAT1, PSPH).GAPDH was used as the loading control. D Kaplan‒Meier analysis of overall survival in TCGA-CRC patients stratified by PHGDH expression. E Left: Metabolite enrichment pathway bubble plot. Middle: Heatmap of differential metabolites. Right: Schematic of serine/one-carbon metabolism. F Heatmap visualization of DEGs in glycine, serine, and threonine metabolism pathways. G ELISA analysis of SAM levels in CXCL7-overexpressing cells and PHGDH-inhibited cells. H TUNEL assays of CXCL7-overexpressing cells transfected with NC-siRNA or PHGDH-siRNA, with or without SAM treatment(scale bar, 50 μm). I The drug sensitivity of CXCL7-overexpressing cells transfected with NC-siRNA or PHGDH-siRNA, with or without SAM treatment. All data are presented as mean ± SD. *P 

2). Serine Metabolism Regulates the Replicative Senescence of Human Dental Pulp Cells through Histone Methylation. Current issues in molecular biology, 2024 (PubMed: 38666909) [IF=2.8]

Application: WB    Species: human    Sample: hDPCs

Figure 2. PHGDH is involved in the cellular senescence of hDPCs. (a) Analysis of the transcription of PHGDH, PSAT1, and PSPH in different passages (P5 and P12) of hDPCs by RT-qPCR. (b) Analysis of PHGDH, PSAT1, and PSPH expression in different passages (P5 and P12) of hDPCs by western blot. (c) Young hDPCs (P5) were treated with different concentrations of NCT—503 and CBR—5884 for 48 h, and cell viability was determined by CCK8 assay. (d) Effects of NCT—503 (20 μM) and CBR—5884 (30 μM) treatment for 48 h on young hDPCs (P5) were determined by SA-β-gal staining, Ki67 staining, and yH2AX staining. In SA-β-gal staining, blue-stained cells are positive cells. In Ki67 staining and yH2AX staining, the blue color in the nucleus shows DAPI staining, the green color in the nucleus shows Ki67 or yH2AX staining. (e) Transcription of LMNB1 and P21 in hDPCs (P5) treated with NCT—503 (20 μM) and CBR—5884 (30 μM) for 48 h was analyzed by RT-qPCR. (f) Crystal violet staining determined colony formation at 7 days after continuous treatment with NCT—503 (20 μM) and 2 days of CBR—5884 (30 μM) treatment. Data were expressed as means ± SD, n = 3 independent experiments. * p < 0.05.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.